

# Diabetic foot ulcers - Pipeline Review - 2019

<https://marketpublishers.com/r/D2EFFB0AD889EN.html>

Date: December 2019

Pages: 100

Price: US\$ 1,250.00 (Single User License)

ID: D2EFFB0AD889EN

## Abstracts

Firstview Insight's Diabetic foot ulcers - Pipeline Review-2019 provides an overview of the pipeline landscape of Diabetic foot ulcers. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Foot ulcers are a common complication of poorly controlled diabetes, forming as a result of skin tissue breaking down and exposing the layers underneath. They're most common under your big toes and the balls of your feet, and they can affect your feet down to the bones.

All people with diabetes can develop foot ulcers and foot pain, but good foot care can help prevent them. Treatment for diabetic foot ulcers and foot pain varies depending on their causes. One of the first signs of a foot ulcer is drainage from your foot that might stain your socks or leak out in your shoe. Unusual swelling, irritation, redness, and odors from one or both feet are also common early symptoms of a foot ulcer.

The most visible sign of a serious foot ulcer is black tissue (called eschar) surrounding the ulcer. This forms because of an absence of healthy blood flow to the area around the ulcer. Partial or complete gangrene, which refers to tissue death due to infections, can appear around the ulcer. In this case, odorous discharge, pain, and numbness can occur.

**Drug Profile Overview:**

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

**Clinical Trial Overview:**

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

**Product Development Activity:**

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

**Company Overview:**

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

**Scope**

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year

## **Reasons To Buy**

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies

Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration

## Contents

### **1. DISEASE OVERVIEW**

- 1.1. Pathophysiology
- 1.2. Symptoms
- 1.3. Etiology
- 1.4. Diagnosis
- 1.5. Etiology
- 1.6. Treatment Algorithm
- 1.7. Treatment Options

### **2. FEATURED NEWS AND PRESS RELEASES, 2018-2062**

### **3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR DIABETIC FOOT ULCERS**

### **4. TREATMENT ALGORITHM**

### **5. CURRENT UNMET NEEDS**

### **6. MARKET TRENDS**

### **7. PIPELINE THERAPEUTICS**

### **8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES**

### **9. LATE STAGE PRODUCTS (PHASE III)**

- 9.1 Drug 1
  - 9.1.1. Product Description
  - 9.1.2. Research and Development
  - 9.1.3. Product Development Activities
- 9.2. Drug 2
  - 9.2.1. Product Description
  - 9.2.2. Research and Development
  - 9.2.3. Product Development Activities

### **10. MID STAGE PRODUCTS (PHASE II)**

## 10.1 Drug 1

- 10.1.1. Product Description
- 10.1.2. Research and Development
- 10.1.3. Product Development Activities

## 10.2. Drug 2

- 10.2.1. Product Description
- 10.2.2. Research and Development
- 10.2.3. Product Development Activities

## **11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)**

### 11.1 Drug 1

- 11.1.1. Product Description
- 11.1.2. Research and Development
- 11.1.3. Product Development Activities

### 11.2. Drug 2

- 11.2.1. Product Description
- 11.2.2. Research and Development
- 11.2.3. Product Development Activities

## **12. DRIVERS OF DIABETIC FOOT ULCERS**

## **13. CONSTRAINTS OF DIABETIC FOOT ULCERS**

## **14. THERAPEUTIC ASSESSMENT**

- 14.1. Assessment by Route of Administration
- 14.2. Assessment by Phase & Route of Administration
- 14.3. Assessment by Molecule Type
- 14.4. Assessment by Phase & Molecule type
- 14.5. Assessment by Target
- 14.6. Assessment by Mechanism of Action

## **15. COLLABORATIONS AND ACQUISITIONS DETAILS**

## **16. DORMANT PRODUCTS**

## **17. DISCONTINUED PRODUCTS**

**18. MARKET TRENDS**

**19. MARKET OPPORTUNITY ASSESSMENT**

**20. UNMET NEEDS**

**21. SWOT ANALYSIS**

**22. APPENDIX**

**23. REPORT METHODOLOGY**

**24. CONSULTING SERVICES**

**25. DISCLAIMER**

## List Of Tables

### LIST OF TABLES

- Table 1: Marketed Diabetic foot ulcers drugs, 2019
- Table 2: Sales of Marketed drugs
- Table 3: Patent expiration details – marketed drugs
- Table 4: Number of Products Under Development for Diabetic foot ulcers
- Table 5: Products under Development by Companies
- Table 6: Late Stage Products
- Table 7: Mid Stage Products
- Table 8: Early Stage Products
- Table 9: Pre-Clinical and Discovery Products
- Table 10: Assessment by Route of Administration
- Table 11: Assessment by Stage and Route of Administration
- Table 12: Assessment by Molecule Type
- Table 13: Assessment by Stage and Molecule Type
- Table 14: Assessment by Target
- Table 15: Assessment by Mechanism of Action
- Table 16: Dormant Products
- Table 17: Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1: Marketed and Pipeline Diabetic foot ulcers drugs, 2019
- Figure 2: Sales of Marketed drugs
- Figure 3: Patent expiration details – marketed drugs
- Figure 4: Number of Products Under Development for Diabetic foot ulcers
- Figure 5: Products under Development by Companies
- Figure 6: Late Stage Products
- Figure 7: Mid Stage Products
- Figure 8: Early Stage Products
- Figure 9: Pre-Clinical and Discovery Products
- Figure 10: Assessment by Route of Administration
- Figure 11: Assessment by Stage and Route of Administration
- Figure 12: Assessment by Molecule Type
- Figure 13: Assessment by Stage and Molecule Type
- Figure 14: Assessment by Target
- Figure 15: Assessment by Mechanism of Action
- Figure 16: Dormant Products
- Figure 17: Discontinued Products



## I would like to order

Product name: Diabetic foot ulcers - Pipeline Review - 2019

Product link: <https://marketpublishers.com/r/D2EFFB0AD889EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D2EFFB0AD889EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970